VivoSeq
Oncology

Colon Carcinoma

16

Pipeline Programs↗

0

Active Trials↗

9

Companies Involved↗

Colon Carcinoma is an emerging landscape with 16 programs across 9 companies. The most active players are Teva, Regeneron, Faron Pharmaceuticals Ltd. 4 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

75/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Teva logo

Teva

1 program

Phase 1Regeneron logo

Regeneron

2 programs

Phase 2F

Faron Pharmaceuticals Ltd

1 program

Phase 2EMD Serono logo

EMD Serono

1 program

Phase 3G

Glaxo Dba Glaxosmithkline

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

63%

Small molecule

10 of 16 classified programs — the dominant modality here.

38%ALL OTHERSMonoclonal antibody638%

Small molecule leads; the ring shows all 16 classified programs, each share of the total. Modality classified for 100% of 16 pipeline programs.

Analysis

Trial Status

4

clinical trials

Completed3 · 75%
Withdrawn1 · 25%

Clinical Trials

Trial Activity

Randomized Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Colon Carcinoma Dukes C
Completed·AAustrian Breast & Colorectal Cancer Study Group·Phase 3·NCT00309530·598 enrolled
Randomized Trial on Adjuvant Chemotherapy in Colon Carcinoma Dukes B
Completed·AAustrian Breast & Colorectal Cancer Study Group·Phase 3·NCT00309543·636 enrolled
Escalating Doses of Oxaliplatin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Children and Adolescents With Extensive Colon Carcinoma
Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02062749·1 enrolled
A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma
Withdrawn·FFaron Pharmaceuticals Ltd·Phase 1/2·NCT05104905

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)